Should ertapenem be given 1 g once daily (od) or twice daily (bd)?

Ertapenem Dosing: Once Daily Administration

Ertapenem should be administered at 1 g once daily (od), not twice daily (bd), for all approved indications in adults with normal renal function. This is the FDA-approved dosing regimen and is consistently recommended across all major international guidelines 1.

Standard Dosing Regimen

Adults (≥13 years)

• Dose: 1 g intravenously once daily 2, 3, 4, 1
• Infusion time: 30 minutes 1
• Duration: Varies by indication (typically 5-14 days for treatment) 2, 1

Pediatric Patients (3 months to 12 years)

• Dose: 15 mg/kg twice daily (maximum 1 g/day) 2, 1
• Note: The twice-daily dosing in pediatrics differs from adult dosing due to different pharmacokinetics in this age group

Key Pharmacologic Rationale

The once-daily dosing of ertapenem is supported by its unique pharmacokinetic profile among carbapenems:

• Extended half-life: Approximately 4 hours (longer than other carbapenems) 1, 5
• High protein binding: 85-95% protein-bound, creating a reservoir effect 6
• Time-dependent killing: Achieves adequate time above MIC (T>MIC) with once-daily dosing 7, 5

Clinical Evidence Supporting Once-Daily Dosing

Multiple guidelines consistently recommend 1 g once daily:

• IDSA/SIS 2010 Guidelines: 1 g every 24 hours for intra-abdominal infections 2
• WSES 2017 Guidelines: 1 g 24-hourly for community-acquired infections 3
• Italian ICOA 2024 Guidelines: 1 g q24h for various intra-abdominal infections 4
• ESCMID 2023 Guidelines: Single daily administration preferred over other carbapenems specifically because of convenient once-daily dosing 8

Special Populations Requiring Dose Adjustment

Renal Impairment

• CrCl >30 mL/min/1.73m²: No adjustment needed (1 g daily) 1
• CrCl ≤30 mL/min/1.73m²: Reduce to 500 mg daily 1
• Hemodialysis patients: 500 mg daily; if given <6 hours before dialysis, give supplemental 150 mg dose after dialysis 1

Critically Ill Patients: A Critical Caveat

Important limitation: Some pharmacokinetic studies suggest standard 1 g once-daily dosing may be inadequate in critically ill ICU patients with:

• Augmented renal clearance
• Increased volume of distribution
• Severe sepsis/septic shock 6, 9

For these patients, consider:

• Continuous infusion after loading dose 5
• Shortened dosing intervals (though not standard practice) 6
• However, no guideline currently recommends twice-daily dosing; instead, alternative carbapenems (meropenem, doripenem, imipenem) with more frequent dosing are preferred for critically ill patients 3, 4

Why Not Twice Daily?

1. No FDA approval for twice-daily dosing in adults 1
2. Pharmacodynamic modeling demonstrates once-daily dosing achieves target T>MIC of ≥40% for susceptible organisms (MIC ≤0.5 mg/L) 7, 5
3. Clinical trial data supporting efficacy used once-daily dosing 1
4. Convenience advantage: Once-daily dosing is specifically cited as a reason to prefer ertapenem over other carbapenems 8

Common Pitfalls to Avoid

• Do not use twice-daily dosing based on pediatric dosing—adults have different pharmacokinetics
• Do not extrapolate from other carbapenems (meropenem, imipenem) which require q6-8h dosing
• For critically ill patients with septic shock: Consider switching to meropenem 1 g q6-8h or other carbapenems with more frequent dosing rather than increasing ertapenem frequency 4
• Monitor for inadequate response in obese patients (BMI >40 kg/m²), as standard dosing may be suboptimal 10, 6